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Method We re-evaluated patients randomised and dosed in OCA
10 mg (n=73), OCA 5–10 mg (n=70, 33 patients titrated from
5 to 10 mg at Month 6), or PBO (n=73) groups during DB
treatment. In the OLE, all patients were initially treated with
5 mg OCA with the option to increase to 10 mg (or later
decrease) based on response and tolerability every 3 months.
Non-invasive measures of liver fibrosis that were assessed were
APRI and liver stiffness measurements (LSM) by transient
elastography.
Results APRI was significantly reduced from baseline to DB
Month 12 in both OCA–treated groups compared to PBO
(p<0.01). PBO patients who initiated OCA during the OLE
phase and patients randomised to OCA 5–10 mg had significant
reductions from baseline to OLE Month 12 in mean APRI score
(p<0.05). The mean APRI score in OCA 10 mg was reduced,
but not significant at OLE Month 12 compared to baseline. Dur-
ing DB and OLE phases, while not significant, the OCA 10 mg
group had mean reductions in LSM, while both OCA 5–10 mg
and PBO groups had mean increases in LSM (Table).
Abstract PTU-097 Figure 1
Conclusion Both LSM and APRI, as non-invasive measures of
liver fibrosis, have been found to be effective in predicting out-
come in patients with PBC. DB and OLE treatment with OCA
resulted in a mean reduction in liver stiffness and significant
improvements in APRI suggesting that with long-term use, OCA
has the potential to improve long term outcomes for patients.
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Introduction The incidence of hepatocellular carcinoma (HCC)
is rising.1,2 Transarterial chemoembolisation (TACE) is frequently
used as a palliative treatment or as a bridge to surgery. TACE
can be offered alone, or together with radiofrequency ablation
(RFA) or Sorafenib. Child-Pugh grade and Barcelona Clinic Liver
Cancer Staging System (BCLC) are useful prognostic tools. Our
aim was to assess outcome for patients receiving TACE over a
6 year period in our regional centre.
Method Patients with HCC were prospectively entered onto a
regional HCC database between 01.01.09–01.01.15. Patients
who underwent TACE (in addition to other therapies) were
identified and clinical data obtained from electronic records.
Child-Pugh grade and BCLC were calculated at time of diagno-
sis, with survival our primary outcome.
Results 497 patients were diagnosed with HCC during this
period. 121 (99 male, 22 females; mean age 68 years) under-
went TACE. 20, 47 and 54 patients had TACE during the peri-
ods 2009–10, 2011–12 and 2013–14 respectively. 102 (84%)
had TACE alone, 6 (5%) each had TACE with RFA and TACE
with Sorafenib, 5 (4%) had TACE then transplant, and two
TACE then resection. 87 (72%), 31 (26%) and 3 (2%) had
Child-Pugh grade A, B and C disease respectively and 38 (31%),
61 (50%), 20 (17%) and 2 (2%) BCLC stage A, B, C and D.
Of the 102 patients having TACE alone, survival is shown in
table:
Overall Child-Pugh BCLC
A B C A/B C/D
number 102 70 29 3 81 21
Survival 1 year 77% 78% 76% 67% 77% 71%
2 year 43% 50% 30% 0 46% 29%
Two year survival for patients having TACE and RFA was
80%; for TACE and Sorafenib 17% and for TACE then trans-
plant/resection 100%.
Conclusion There has been a steady rise in the number of patients
with HCC undergoing TACE procedures in our unit. Survival fol-
lowing TACE compares favourably to other studies.3,4
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Introduction Severe alcoholic hepatitis (SAH) has a high mortal-
ity and only corticosteroids have a proven short term benefit.
Early prediction of treatment response would allow selection of
appropriate patients who would benefit from corticosteroids. We
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have previously reported that a functional bioassay measuring in
vitro corticosteroid sensitivity, DILPA, accurately predicts
6 month survival in patients with SAH1. However, due to its
requirement for radiation it lacked clinical translatability and a
second generation assay, bromodeoxyuridine (BrdU) incorpora-
tion in lymphocyte steroid sensitivity assay (BLISS) assay, has
been developed and validated in healthy controls2. In this study
we aimed to generate preliminary data to determine whether the
BLISS assay can be used to predict clinical outcome in patients
with SAH.
Method Peripheral blood was drawn from patients with a clinical
diagnosis of SAH (discriminant function [DF] >32). All partici-
pants gave informed consent and ethical approval was obtained
from the NHS Health Research Authority. All patients were
treated with corticosteroids for 28 days. The primary outcome
measure was 90 day survival. Peripheral blood mononuclear
cells, isolated by density gradient centrifugation, were stimulated
with lymphocyte mitogen in the absence or presence of dexame-
thasone and cultured for 48 hours per previously described pro-
tocol2. Proliferation was determined by measuring BrdU
incorporation using a commercial kit. The maximum suppression
of proliferation by corticosteroids (Imax) was determined.
Results 10 patients were recruited (7 female, median age 50)
with mean DF 75. 6 patients survived to 90 days and had a sig-
nificantly higher Imax than non-survivors (27% v 12%;
p=0.01) with clear separation between groups (figure 1). Survi-
vors also had lower Lille score than non-survivors (0.20 v 0.79;
p=0.02) but in applying the established threshold of 0.45, 1
patient was misclassified as a steroid non-responder. However,
Imax did not correlate with Lille score (r2=0.21) or percentage
change in bilirubin from day 0 to day 7 (r2=0.10).
Abstract PTU-099 Figure 1
Conclusion The BLISS assay clearly differentiates survivors from
non-survivors at 90 days and shows potential for use as a stratifi-
cation tool in the initial management of patients with SAH. Fur-
ther validation in a larger multicentre cohort is planned.
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Introduction Obeticholic acid (OCA) is a potent and selective
farnesoid X receptor (FXR) agonist under investigation for treat-
ment of primary biliary cholangitis (PBC) and other chronic liver
diseases. POISE was a double-blind, placebo-controlled, rando-
mised Phase 3 study examining the efficacy of OCA in PBC. The
objective of this post-hoc analysis was to assess the efficacy of
OCA in the subset of patients with cirrhosis who were at higher
risk of progression to liver-related outcomes or death.
Method We randomised and dosed 216 patients 1:1:1 with pla-
cebo (PBO) (n=73), OCA 5–10 mg (n=70, titrated to 10 mg
after 6 months based on response and tolerability) or OCA
10 mg (n=73). Inclusion criteria included PBC diagnosis,
ALP1.67x ULN and/or total bilirubin (BILI) >ULN to <2x
ULN, stable UDCA dose or intolerance to UDCA. Patients were
considered to have cirrhosis if they met one of the following cri-
teria: biopsy-proven cirrhosis, transient elastography
of 16.9 kPa, or history of cirrhosis. The primary composite
endpoint was an ALP<1.67x ULN with 15% reduction in ALP
and BILI £ULN after 12 months.
Results Cirrhosis was present in approximately 17% of patients
in POISE: PBO, n=13; OCA 5–10 mg, n=13; OCA 10 mg,
n=10. At month 12, 54% (p<0.05) of patients in the OCA 5–
10 mg group and 40% (p=0.06) in the OCA 10 mg group met
the primary composite endpoint compared to 8% of PBO
patients with cirrhosis. The table shows significant differences in
ALP and BILI between PBO and both OCA groups after 12
months. BILI increased on PBO; however, it remained stable in
both OCA groups after 12 months of treatment. Pruritus was
the most common adverse event in patients with cirrhosis, affect-
ing 23%, 69%, and 80% of patients in the PBO, OCA 5–10 mg,
and OCA 10 mg groups, respectively.
Conclusion In this post-hoc analysis, no additional safety con-
cerns due to OCA were observed in the subgroup of OCA-
treated patients with cirrhosis, and OCA treatment resulted in
significant improvements in biochemical markers associated with
disease progression. The percentage of patients achieving the pri-
mary composite endpoint on OCA was comparable in patients
with cirrhosis and non-cirrhotic patients. These results suggest
that OCA may play a beneficial role in preservation of the func-
tional capacity of residual liver tissue in cirrhotic patients.
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